Venn Life Sciences Holdings plc (LON:VENN) delivered strong revenue and order book growth in 2016 as it integrated Dutch drug consultancy Kinesis Pharma BV into the business.
The strong momentum in 2016 has continued into this year to date with €5.7mln in contract wins in January and February.
“We will continue to expand our geographical coverage and further develop emerging areas of specialism during 2017. Our industry sector continues to deliver good growth and clear opportunities exist for Venn to grow both organically and through acquisition”, said chief executive Tony Richardson.
See the article in full at Proactiveinvestors.co.uk